The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001448" target="_blank" >RIV/00064190:_____/26:10001448 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.21873/invivo.14261" target="_blank" >https://doi.org/10.21873/invivo.14261</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/invivo.14261" target="_blank" >10.21873/invivo.14261</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab

Popis výsledku v původním jazyce

Background/Aim: Immune checkpoint inhibitors (ICI), including nivolumab, have become the cornerstone of systemic treatment in metastatic renal cell carcinoma (mRCC). Blood-derived biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) have emerged as important indicators of systemic inflammatory and immune status. The aim of this study was to evaluate the prognostic and predictive value of NLR, PLR, and LMR at baseline and their early dynamics during nivolumab monotherapy in mRCC patients. Patients and Methods: The associations of baseline NLR, PLR, LMR and their changes (Delta) after one month of nivolumab therapy with patient outcomes including progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were retrospectively analyzed. Results: In total, 310 patients were included. Baseline NLR &gt;= 4 (PFS: HR=2.136, p&lt;0.001; OS: HR=2.442, p&lt;0.001), PLR &gt;= 310 (PFS: HR=2.383,p&lt;0.001; HR=3.604,p&lt;0.001),and LMR &lt;1.5 (PFS: HR=1.802,p=0.002; OS: HR=2.273,p&lt;0.001) were independent factors for inferior PFS and OS. Regarding early changes, Delta NLR &gt;= 2 (PFS: HR=3.019, p&lt;0.001; OS: HR=3.095, p&lt;0.001) and Delta PLR &gt;= 20 (PFS: HR=1.436, p=0.024; OS: HR=1.719, p=0.006) were independent factors for inferior PFS and OS, while Delta LMR &lt;0 was independent factor for inferior PFS (HR=1.458, p=0.030). Lower ORR was associated with baseline NLR &gt;= 4 (p=0.020), Delta NLR &gt;= 2 (p=0.010), and Delta PLR &gt;= 20 (p=0.019). Conclusion: The results of the present study suggest a prognostic role for baseline NLR, PLR and LMR. In addition, an early change in NLR and PLR is associated with patient outcome and represents a candidate surrogate biomarker for monitoring the immunotherapy response.

Název v anglickém jazyce

The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab

Popis výsledku anglicky

Background/Aim: Immune checkpoint inhibitors (ICI), including nivolumab, have become the cornerstone of systemic treatment in metastatic renal cell carcinoma (mRCC). Blood-derived biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) have emerged as important indicators of systemic inflammatory and immune status. The aim of this study was to evaluate the prognostic and predictive value of NLR, PLR, and LMR at baseline and their early dynamics during nivolumab monotherapy in mRCC patients. Patients and Methods: The associations of baseline NLR, PLR, LMR and their changes (Delta) after one month of nivolumab therapy with patient outcomes including progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were retrospectively analyzed. Results: In total, 310 patients were included. Baseline NLR &gt;= 4 (PFS: HR=2.136, p&lt;0.001; OS: HR=2.442, p&lt;0.001), PLR &gt;= 310 (PFS: HR=2.383,p&lt;0.001; HR=3.604,p&lt;0.001),and LMR &lt;1.5 (PFS: HR=1.802,p=0.002; OS: HR=2.273,p&lt;0.001) were independent factors for inferior PFS and OS. Regarding early changes, Delta NLR &gt;= 2 (PFS: HR=3.019, p&lt;0.001; OS: HR=3.095, p&lt;0.001) and Delta PLR &gt;= 20 (PFS: HR=1.436, p=0.024; OS: HR=1.719, p=0.006) were independent factors for inferior PFS and OS, while Delta LMR &lt;0 was independent factor for inferior PFS (HR=1.458, p=0.030). Lower ORR was associated with baseline NLR &gt;= 4 (p=0.020), Delta NLR &gt;= 2 (p=0.010), and Delta PLR &gt;= 20 (p=0.019). Conclusion: The results of the present study suggest a prognostic role for baseline NLR, PLR and LMR. In addition, an early change in NLR and PLR is associated with patient outcome and represents a candidate surrogate biomarker for monitoring the immunotherapy response.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2026

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

IN VIVO

ISSN

0258-851X

e-ISSN

1791-7549

Svazek periodika

40

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

15

Strana od-do

1065-1079

Kód UT WoS článku

001708468900030

EID výsledku v databázi Scopus

2-s2.0-105031600627